Literature DB >> 2580175

Angiotensin-converting enzyme inhibition: renal aspect.

N K Hollenberg.   

Abstract

Compelling arguments can be made for a local, intrarenal role as angiotensin's first action in phylogeny, with additional cardiovascular and endocrine responses arising later. Perhaps for that reason the vascular bed of the kidney is especially responsive to angiotensin II. Conversely, when the renin-angiotensin system is activated, as it is when sodium intake is restricted or diuretics are administered, the renal blood supply shows the most striking and consistent vasodilatation among vascular beds assessed after converting enzyme inhibition. When renal vascular tone is increased in patients with essential hypertension, converting enzyme inhibitors induce a potentiated acute renal vascular response: renal blood flow increases more than it does in normal subjects, with an associated consistent early increase in sodium excretion and an occasional increase in glomerular filtration rate. Reduced aldosterone release consequent on the block of angiotensin II formation also contributes to the natriuresis and results in positive potassium balance. With long-term therapy renal function tends to be well maintained. The response to converting enzyme inhibition in renal artery stenosis is more complex: as perfusion pressure distal to the stenosis falls there is typical afferent arteriolar dilatation and glomerular capillary pressure tends to be maintained by a rise in postglomerular resistance. To the extent that this is angiotensin mediated, suppression of angiotensin formation can reduce glomerular capillary pressure and thus filtration rate. This is well tolerated in the patient with unilateral stenosis and a healthy contralateral kidney, but can provoke renal failure where the stenosis is bilateral or involves a solitary kidney.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580175     DOI: 10.1097/00005344-198507001-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Angiotensin-converting enzyme inhibitors or calcium channel blockers? An overview.

Authors:  H Gavras
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 3.  Drug therapy of renovascular hypertension.

Authors:  Talma Rosenthal
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 4.  Comparative cardiovascular effects of drugs used for hypertension.

Authors:  M Burnier; B Waeber; J Nussberger; H R Brunner
Journal:  Drugs       Date:  1990       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.